The Myasthenia Gravis Foundation of America (MGFA) is the only national volunteer health agency in the United States dedicated solely to the fight against myasthenia gravis. MGFA serves patients, their families and caregivers through a network of chapters, support groups and programs. Each chapter shares the vision of a world without MG.
Myasthenia gravis (pronounced My-as-theen-ee-a Grav-us) comes from the Greek and Latin words meaning "grave muscular weakness." The most common form of MG is a chronic autoimmune neuromuscular disorder that is characterized by fluctuating weakness of the voluntary muscle groups. To learn more click here.
The MG Walk, which generates awareness, renews hope, and creates a community of support and strength, has named "MG Walk Heroes" across each of the cities in which the Walks are taking place across the nation. Click here to read these heroes' stories and how they are raising awareness to help find a cure for MG.
Are you hoping to have a baby someday?
Are you a young woman and an MG patient? Want to know more about the impact of MG on becoming a mother and how it might affect your pregnancy and childbirth? If you answered yes to these questions, you need to participate in the Myasthenia Gravis Research Foundation’s upcoming webinar on MG and Pregnancy, with Robert Ruff, MD. A date for the program will be announced in coming weeks. In the meantime, MGFA is building a mailing list of young women interested in participating. To receive the announcement directly, please send your contact information to Karimah Day at email@example.com. Once we have program dates set, you’ll hear from us with the details.
The Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) is currently looking for people with myasthenia gravis (MG) to be part of a research study.
Rituximab Study FAQs
Additional Rituximab Study Information
Alexion Pharmaceuticals is conducting a clinical trial to determine if eculizumab is effective for the treatment of patients with refractory generalized Myasthenia Gravis (gMG). This is a global trial, with approximately 100 sites in North and South America, Europe and Asian-Pacific countries are taking part. This study is currently looking for patients with refractory gMG. Read more here.
We would like to welcome MGFA members to a new column that will appear quarterly. Our goal is to highlight some of the latest developments in research related to neuromuscular junction disorders. Every column should include new developments in myasthenia gravis (MG), but we will be covering other disease states as well. For this inaugural column, we will lead with congenital myasthenic syndrome. Read more here.
The Nurses Advisory Board is now offering an online Continuing Education program for 2 contact hours for Nurses. For more information on how to participate, please click here.
The AANN webcast recording from the "Care of the Patient with Myasthenia Gravis" is now available. Please click here to listen.
The Myasthenia Gravis Foundation of America requests submission of proposals to support pilot studies that are highly focused and innovative with a clear plan that will lead to new federal, pharmaceutical, or private foundation supported investigations. Learn more here.
Dr. Ted Burns from the University of Virginia and a member of the M/SAB is producing a series of patient oriented podcasts for MGFA with information on the diagnosis, treatment, and management of MG. A podcast on The Benefits of Exercise in the Care of Patients with Myasthenia Gravis was produced in March 2012. To view and listen to the podcast series, click here.
2014 National Conference
To view the National Conference Video Presentations click here.
Save - the - date The 2015 National Conference will be held April 28 - May 1 at the Wyndham San Diego Bayside in San Diego, CA. To make your hotel reservations click here.
Registration details coming soon.
There is no known cure for MG, but there are effective treatments that allow many-but not all-people with MG to lead full lives. Although the treatments will not cure MG, patients may have significant improvement in their muscle strength.